Author/Authors :
Taghizadeh Kermani، Ali نويسنده Surgical Oncology Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , , Vakili، Rosita نويسنده Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran , , Dadkhah، Samaneh نويسنده Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran , , Jafarian، Amir Hossein نويسنده Department of Pathology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran , , Bagheri، Reza نويسنده Assistant Professor, Islamic Azad University, Baft Branch ,
Abstract :
Background
HER-2/neu overexpression has been reported in various human cancers and identified as a significant predictor of poor survival. In this study HER-2/neu overexpression and its associations with clinicopathological characteristics were evaluated in patients with esophageal squamous cell carcinoma (ESCC).
Methods
This cross-sectional study was performed on 64 patients with histological diagnosis of primary ESCC who underwent surgery for curative treatment. Immunohistochemistry (IHC) was used to assess expression of HER-2/neu receptor in formalin-fixed paraffin-embedded tissue blocks.
Results
The mean age of patients was 60.1 ± 1.28 years. The overall HER2 expression was observed in 51.5% of ESCC patients without considering IHC scores. HER2/neu overexpression (6%) was significantly associated with the tumor differentiation (P < 0.001). 20.3% of cases were stage I, 67.2% stage II, and 12.5% stage III. 17 patients (26.2%) had vascular invasion, 12 patients (18.8%) had neuronal invasion and 7 patients (10.9%) had invasion to margins. Nine of 12 patients with HER-2/neu over expression had thoracic tumors and only three of them had an abdominal ESCC.
Conclusions
No significant correlations were found between HER2/neu overexpression and gender, age, tumor invasion, location of tumor, TNM stages and stage of tumor in patients with ESCC.
